Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02686502
Other study ID # TYH2016215
Secondary ID 575/31/2015
Status Completed
Phase N/A
First received
Last updated
Start date April 2016
Est. completion date December 2019

Study information

Verified date May 2022
Source University of Helsinki
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the effect and usability of mobile and cloud technology -based intervention on lifestyle modification in 18-40 year obese and overweight subjects. The study has a dose-response design with three randomized subjects groups from Mode 1 to Mode 3 with increasing intensity of intervention (guidance, exercise program, diet, support). The special focus of this study is on motivation and use of music and mobile health devices as motivational tools to support individualized exercise training, healthy diet and overall healthy life style.


Description:

Obesity negatively impacts health in many ways. It is associated with metabolic diseases and mood disorders and in women pregnancy outcome as well as the health of the offspring. The modern evolution of societies steers populations towards a profound sedentary lifestyle. Physical activity brings about health benefits, however, the risk reduction for chronic diseases remains significantly greater for fitness than physical activity per se. The recent knowledge suggest Individualized approach rather than general guidelines for exercise in prevention-oriented strategies. In this study we compare three different intensities of lifestyle intervention: 1) general guidelines for healthy exercise and diet, 2) individual program,and 3) highly individual program. Individual programs will be based on pre-examinations including interview and clinical exercise test. Mobile and cloud technologies will be used to collect data and steer the subjects´ lifestyles and daily activities and together with music to motivate them. The duration of the active intervention is 3 months and it will continue on a self-governing basis up to 1 year. The primary outcome is maximal oxygen consumption (VO2max), and secondary outcomes are physical activity, cardio-respiratory and cardiovascular parameters, blood volume, total hemoglobin mass, metabolic health along with chronic low-grade inflammation and well-being.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date December 2019
Est. primary completion date December 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - BMI = 27,5 kg/m2 - estimated by health care personnel to benefit from lifestyle modification Exclusion Criteria: - inability to perform exercise testing and intervention (physical, mental or other reason) - not able to operate in Finnish (some applications only in Finnish for the time being) - severe anemia (Hb<108 g/l for women and < 124 g/l for men) - smoking (disturbs autonomic nervous system measurements) - regular medication affecting glucose metabolism (excluding insulin) or autonomic nervous system (e.g. beta blockers, SSRI) - ongoing pregnancy or breast feeding - prisoner

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Lifestyle
As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.

Locations

Country Name City State
Finland Helsinki University Hospital Helsinki
Finland Vantaa Health Care and Social Services Vantaa

Sponsors (5)

Lead Sponsor Collaborator
University of Helsinki Finnish Institute of Occupational Health, Helsinki University Central Hospital, University of Western Ontario, Canada, VTT Technical Research Centre of Finland

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from measured baseline maximal O2 uptake (VO2max) at 3 months 3 months
Secondary Change from baseline quality of life at 3 months Rand-36 questionnaire 3 months
Secondary Change from baseline total plasma cholesterol at 3 months 3 months
Secondary Change from baseline physical activity at 3 months The International Physical Activity Questionnaire short version (IPAQ-S) 3 months
Secondary Change from baseline body weight at 3 months weight in kilograms 3 months
Secondary Change from baseline quality of life at 1 year Rand-36 questionnaire 1 year
Secondary Change from baseline physical activity at 1 year The International Physical Activity Questionnaire short version (IPAQ-S) 1 year
Secondary Change from baseline body weight at 1 year weight in kilograms 1 year
Secondary Change from baseline total plasma cholesterol at 1 year 1 year
Secondary Change from baseline plasma HDL cholesterol at 3 months 3 months
Secondary Change from baseline plasma HDL cholesterol at 1 year 1 year
Secondary Change from baseline plasma LDL cholesterol at 3 months 3 months
Secondary Change from baseline plasma LDL cholesterol at 1 year 1 year
Secondary Change from baseline plasma triglycerides at 3 months 3 months
Secondary Change from baseline plasma triglycerides at 1 year 1 year
Secondary Change from baseline blood glucose balance at 3 months Blood glucose balance assessed by 75-g 2 h oral glucose tolerance test 3 months
Secondary Change from baseline blood glucose balance at 1 year Blood glucose balance assessed by 75-g 2 h oral glucose tolerance test 1 year
Secondary Change from baseline fasting plasma insulin at 3 months 3 months
Secondary Change from baseline fasting plasma insulin at 1 year 1 year
Secondary Change from baseline body composition at 3 months Body composition assessed by bioimpedance 3 months
Secondary Change from baseline mood at 3 months PANAS questionnaire 3 months
Secondary Change from baseline mood at 1 year PANAS questionnaire 1 year
Secondary Change from baseline work productivity at 3 months Work Productivity and Activity Impairment Questionnaire (WPAI) 3 months
Secondary Change from baseline work productivity at 1 year Work Productivity and Activity Impairment Questionnaire (WPAI) 1 year
Secondary Change from baseline sexual functions at 3 months (females) The Female Sexual Function Index (FSFI) 3 months
Secondary Change from baseline sexual functions at 1 year (females) The Female Sexual Function Index (FSFI) 1 year
Secondary Change from baseline music consumption at 3 months Music in Mood Regulation questionnaire (MMR) 3 months
Secondary Change from baseline music consumption at 1 year Music in Mood Regulation questionnaire (MMR) 1 year
Secondary Change from baseline calorie intake at 3 months Food diary filled during 3 consecutive days every 2 weeks 3 months
Secondary Change from baseline calorie intake at 1 year Food diary filled during 3 consecutive days every 2 weeks 1 year
Secondary Change from baseline heart rate variability at 3 months 3 day electrocardiography monitoring 3 months
Secondary Change from baseline heart rate variability at 1 year 3 day electrocardiography monitoring 1 year
Secondary Change from baseline protein intake at 3 months Food diary filled during 3 consecutive days every 2 weeks 3 months
Secondary Change from baseline protein intake at 1 year Food diary filled during 3 consecutive days every 2 weeks 1 year
Secondary Change from baseline fat intake at 3 months Food diary filled during 3 consecutive days every 2 weeks 3 months
Secondary Change from baseline fat intake at 1 year Food diary filled during 3 consecutive days every 2 weeks 1 year
Secondary Change from baseline carbohydrate intake at 3 months Food diary filled during 3 consecutive days every 2 weeks 3 months
Secondary Change from baseline carbohydrate intake at 1 year Food diary filled during 3 consecutive days every 2 weeks 1 year
Secondary Height height measured in centimeters 0 months
Secondary Stability of personality Five Factor Personality test 0 months
Secondary Stability of personality Five Factor Personality test 3 months
Secondary Stability of personality Five Factor Personality test 1 year
Secondary Change from baseline depression at 3 months Beck questionnaire 3 months
Secondary Change from baseline depression at 1 year Beck questionnaire 1 year
Secondary Change from baseline waist-hip-ratio at 3 months 3 months
Secondary Change from baseline waist-hip-ratio at 1 year 1 year
Secondary Change from baseline plasma ferritin (P-Ferrit) level at 3 months 3 months
Secondary Change from baseline plasma ferritin (P-Ferrit) level at 1 year 1 year
Secondary Change from baseline plasma transferrin receptor (P-TfR) level at 3 months 3 months
Secondary Change from baseline plasma transferrin receptor (P-TfR) level at 1 year 1 year
Secondary Change from baseline plasma sensitive C-reactive protein (CRP) level at 3 months 3 months
Secondary Change from baseline plasma sensitive C-reactive protein (CRP) level at 1 year 1 year
Secondary Change from baseline plasma tumor necrosis factor alpha alpha (P-TNF alpha) level at 3 months 3 months
Secondary Change from baseline plasma tumor necrosis factor alpha alpha (P-TNF alpha) level at 1 year 1 year
Secondary Change from baseline plasma Interleukin-6 (IL6) level at 3 months 3 months
Secondary Change from baseline plasma Interleukin-6 (IL-6) level at 1 year 1 year
Secondary Change from baseline plasma Interleukin-10 (IL-10) level at 3 months 3 months
Secondary Change from baseline plasma IInterleukin-10 (IL-10) level at 1 year 1 year
Secondary Change from baseline plasma Interleukin-15 (IL-15) level at 3 months 3 months
Secondary Change from baseline plasma Interleukin-15 (IL-15) level at 1 year 1 year
Secondary Change from baseline plasma Interleukin-8 (IL-8) level at 3 months 3 months
Secondary Change from baseline plasma Interleukin-8 (IL-8) level at 1 year 1 year
Secondary Change from baseline plasma Interleukin-1 beta (IL-1 beta) level at 3 months 3 months
Secondary Change from baseline plasma Interleukin-1 beta (IL-1 beta) level at 1 year 1 year
Secondary Change from baseline body mass index (BMI) at 3 months BMI in kg/m^2 3 months
Secondary Change from baseline body mass index (BMI) at 1 year BMI in kg/m^2 1 year
Secondary Change from estimated (non-exercise questionnaire) baseline maximal O2 uptake (VO2max) at 3 months 3 months
Secondary Change from estimated (non-exercise questionnaire) baseline maximal O2 uptake (VO2max) at 1 year 1 year
Secondary Change from estimated (step test) baseline VO2max at 3 months 3 months
Secondary Change from estimated (step test) baseline VO2max at 1 year 1 year
Secondary Change from estimated (submaximal cycle ergometer exercise) baseline VO2max at 3 months 3 months
Secondary Change from baseline maximal work rate (WR) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) pulmonary ventilation (VE) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) alveolar ventilation (VA) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) breathing frequency (Bf) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) tidal volume (VT) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) tidal volume - dead space ratio (VD/VT) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) end tidal O2 (PETO2) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) end tidal CO2 (PETCO2) at 3 months 3 months
Secondary Change from baseline submaximal (work rate specific) VO2 at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) CO2 production (VCO2) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) respiratory exchange ratio (RER) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) ventilatory equivalent for O2 uptake (VE/VO2) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) ventilatory equivalent for CO2 production (VE/VCO2) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) O2 pulse (VO2/HR) at 3 months 3 months
Secondary Change from baseline resting heart rate (HR) at 3 months 3 months
Secondary Change from baseline resting heart rate (HR) at 1 year 1 year
Secondary Change from baseline resting blood pressure (BP, systolic, diastolic, pulse, mean) at 3 months 3 months
Secondary Change from baseline resting blood pressure (BP, systolic, diastolic, pulse, mean) at 1 year 1 year
Secondary Change from baseline maximal and submaximal (work rate specific) heart rate (HR) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) arterial blood pressure (BP, systolic, diastolic, pulse, mean) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) cardiac output (Q) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) stroke volume (SV) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) end-diastolic volume (EDV) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) ejection fraction (EF) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) cardiac index at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) contractility index at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) estimate of left ventricular ejection time at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) left cardiac work index at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) early diastolic function ratio at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) calculated arteriovenous O2 difference ((a-v)O2) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) arterial O2 saturation (SpO2) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) calculated arterial O2 content (CaO2) heart rate (HR) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) calculated O2 delivery (QaO2) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) calculated O2 extraction (O2ext) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) calculated systemic vascular resistance (SVR) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) metabolic equivalent (MET) at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) tissue saturation index (TSI) in skeletal muscle and cerebral tissue at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) oxyhemoglobin concentration (O2Hb) in skeletal muscle and cerebral tissue at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) deoxyhemoglobin concentration (HHb) in skeletal muscle and cerebral tissue at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) total hemoglobin concentration (Hbtot) in skeletal muscle and cerebral tissue at 3 months 3 months
Secondary Change from baseline maximal and submaximal (work rate specific) estimated regional blood flow (BFe) at 3 months 3 months
Secondary Change from baseline ankle-brachial blood pressure index (ABI) at 3 months 3 months
Secondary Change from baseline cardio-ankle vascular index (CAVI) at 3 months 3 months
Secondary Change from baseline blood pressure variability (BPV) at 3 months 3 months
Secondary Change from baseline baroreflex sensitivity (BRS) at 3 months 3 months
Secondary Change from baseline postural sway during orthostatic test at 3 months 3 months
Secondary Change from baseline nocturnal heart rate variability (HRVn) at 3 months 3 months
Secondary Change from baseline heart rate on-kinetics and off-kinetics during an exercise test at 3 months 3 months
Secondary Change from baseline alveolar gas exchange on-kinetics and off-kinetics during an exercise test at 3 months 3 months
Secondary Change from baseline tissue oxygenation on-kinetics and off-kinetics during an exercise test at 3 months 3 months
Secondary Change from baseline hemoglobin concentration ([Hb]) at 3 months 3 months
Secondary Change from baseline hemoglobin concentration ([Hb]) at 1 year 1 year
Secondary Change from baseline hematocrit (Hct) at 3 months 3 months
Secondary Change from baseline hematocrit (Hct) at 1 year 1 year
Secondary Change from baseline blood count at 3 months 3 months
Secondary Change from baseline blood count at 1 year 1 year
Secondary Change from baseline blood volume (BV) at 3 months 3 months
Secondary Change from baseline total hemoglobin mass (tHb-mass]) at 3 months 3 months
Secondary Change from baseline erythrocyte volume (EV) at 3 months 3 months
Secondary Change from baseline erythrocyte volume (EV) at 1 year 1 year
Secondary Change from baseline plasma volume (PV) at 3 months 3 months
Secondary Change from baseline glycosylated hemoglobin (HbA1c) at 3 months 3 months
Secondary Change from baseline glycosylated hemoglobin (HbA1c) at 1 year 1 year
Secondary Change from baseline homeostasis model assessment of insulin resistance (HOMA-IR) at 3 months 3 months
Secondary Change from baseline homeostasis model assessment of insulin resistance (HOMA-IR) at 1 year 1 year
Secondary Change from baseline blood interleukin 2 (IL-2) at 3 months 3 months
Secondary Change from baseline blood interleukin 2 (IL-2) at 1 year 1 year
Secondary Change from baseline blood interleukin (IL-4) at 3 months 3 months
Secondary Change from baseline blood interleukin (IL-4) at 1 year 1 year
Secondary Change from baseline blood interleukin 5 (IL-5) at 3 months 3 months
Secondary Change from baseline blood interleukin 5 (IL-5) at 1 year 1 year
Secondary Change from baseline blood granulocyte-macrophage colony-stimulating factor (GM-CSF) at 3 months 3 months
Secondary Change from baseline blood granulocyte-macrophage colony-stimulating factor (GM-CSF) at 1 year 1 year
Secondary Change from baseline blood interferon gamma (IFN?) at 3 months 3 months
Secondary Change from baseline blood interferon gamma (IFN?) at 1 year 1 year
Secondary Change from baseline blood resistin at 3 months 3 months
Secondary Change from baseline blood resistin at 1 year 1 year
Secondary Change from baseline blood leptin at 3 months 3 months
Secondary Change from baseline blood leptin at 1 year 1 year
Secondary Change from baseline blood adiponectin at 3 months 3 months
Secondary Change from baseline blood adiponectin at 1 year 1 year
Secondary Change from baseline Forced Vital Capacity (FVC) at 3 months 3 months
Secondary Change from baseline Forced Expiratory Volume in the 1st second (FEV1) at 3 months 3 months
Secondary Change from baseline The percentage of total expired volume that was expired in the first second (FEV1%) at 3 months 3 months
Secondary Change from baseline Forced Inspiratory Vital Capacity (FIV) at 3 months 3 months
Secondary Change from baseline Peak Expiratory Flow (PEF) at 3 months 3 months
Secondary Change from baseline Peak Inspiratory Flow (PIF) at 3 months 3 months
Secondary Change from baseline Forced Expiratory Flow between 25% and 75% of FVC (FEF2575) at 3 months 3 months
Secondary Change from baseline Forced Expiratory Flow at 25% of expired volume during FVC test (FEF25) at 3 months 3 months
Secondary Change from baseline Forced Expiratory Flow at 50% of expired volume during FVC test (FEF50) at 3 months 3 months
Secondary Change from baseline Forced Expiratory Flow at 75% of expired volume during FVC test (FEF75) at 3 months 3 months
Secondary Change from baseline Forced Expiratory Time (FET) at 3 months 3 months
Secondary Change from baseline sleep time cumulatively to 3 months 3 months
Secondary Change from baseline sleep time cumulatively to 1 year 1 year
Secondary Change from baseline self-reported feelings on him-/herself, health, outlook, intimate relationship/marriage, family, friends, sex, work, studies, hobbies, money, pets, technology and traffic cumulatively to 3 months 3 months
Secondary Change from baseline self-reported feelings on him-/herself, health, outlook, intimate relationship/marriage, family, friends, sex, work, studies, hobbies, money, pets, technology and traffic cumulatively to 1 year 1 year
Secondary Change from baseline possible obstructive sleep apnea (OSA) to 3 months 3 months
Secondary Change from baseline calculated Wellness Index (WI) at 3 months 3 months
Secondary Change from baseline calculated Wellness Index (WI) at 1 year 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2